Pantalone KM, et al. - Using real-world data, researchers evaluated the effects of “clinical” and “intensification inertia” by assessing the impact of different intensification interventions on the probability of HbA_1c goal attainment. Using electronic health records (Cleveland Clinic, 2005–2016), the investigators identified 7,389 people with type 2 diabetes mellitus and HbA_1c ≥ 53 mmol/mol (≥ 7.0%), despite a stable regimen of two oral antihyperglycemic drugs for ≥ 6 months. The participants were stratified by the HbA_1c index and analyzed for a pharmacological intensification period of 6 months, followed by 12 additional months, for the achievement of the HbA_1c target (< 53 mmol/mol). In people with the highest HbA_1c index (≥ 75 mmol/mol [≥ 9.0%]), numerical—but not statistically significant—differences in the probability of achieving the HbA_1c target by intensification type were most noticeable. Findings revealed that injectable therapy demonstrated trends towards greater glycemic control benefits in this group.